Investing in Life Science – Measuring Returns and Impact
Registration for this event is now closed as we are at capacity. Please contact email@example.com to be added to the waiting list.
It is not questioned anymore that investing in science has a beneficial impact on societies and countries’ economic growth. The UK, which is in the average of OECD countries, still dedicates over 1.6% of its GPD to science investment that surely ambitions to translate into economic growth.
What is questioned however is how to actually measure this impact and therefore which form this investment should take. A large panel is available from research grants to infrastructure, cash and operation support but how to balance these in order to create a competitive advantage that leverage further investment and workforce.
This event will provide examples of government’s investment in life sciences from the UK and Canada, importantly the rational that supported them and will open the discussion on the resulting impact it had locally and nationally.
There are lots of ongoing discussions on how to measure the impact of science investment in economic growth and actually an interesting summary of the OECD Blue Sky Forum on Science and Innovation Indicator can be found here. This event will look more at the stories than the indicators themselves and therefore should appeal to any research organisations, science parks, companies who are interested in understanding better the general investment dynamic and how they can contribute to it.
13.00 Networking over coffees and teas
13.30 Welcome from One Nucleus and Canadian High Commission
Alicia Gailliez, One Nucleus
Taylor Hladik, Counsellor and senior trade commissioner
13.40 Investing in Science
13.40 Investing in drug discovery in Quebec
Pierre-Yves Desbiens, Institute Neomed
14.00 The Biomedical Catalyst
Michael Kipping, Innovate UK
Davidson Ateh, BioMoti
14.20 Investing in Artificial Intelligence
Shelley Epstein, Imagia
14.40 Strategic Developments in Cell and Gene Therapy
Fungayi Chidothe, Cell and Gene Therapy Catapult
15.00 The IRICoR Solution in Drug Discovery
Nadine Beauger, IRICoR
15.20 Coffee Break
15.50 Measuring impact
A presentation from a concrete example of measuring the impact of investment in science followed by a panel discussion from witnesses of large scale investment, their positive impact but pitfalls to avoid to maintain the dynamic
Measuring investment in life science impact from a research perspective
Ian Viney, MRC
16.10 Panel discussion on measuring impact
Chair: Louise Leong, Life Science Consultant
Paule Deblois, SOVAR
Kath MacKay, Aldelrey Park
Martino Picardo, Discovery Park
Debbie Laubach, MediWales
16.55 Closing remarks
This is a free event but please still register.
Please note for security at this event you are required to bring Photo ID. Also, please be aware suitcases are not allowed into the building and any electronic devices larger than a mobile will need to go into lockers. Please contact us if you have any queries.
London SW1Y 5BJ